Assessment — idea-019

A home-use prescription abdominal binder that inflates when the wearer stands, for symptomatic neurogenic orthostatic hypotension in Parkinson disease, MSA and pure autonomic failure. It is built to be paid for as Part B durable medical equipment.

This file carries no confidence tags. It cites them: [claim N: tag] reads claim N of the candidate file with the tag it carries there, and check_assessment.py refuses a citation that disagrees. It moves no score, no stage: and no status:.

How these gradings were made, stated up front because they are not fully prospective. This is the first assessment of idea-019, stated on 2026-09-29 against P0 the original shape, the shape as generated. Every consequence class below was set on 2026-09-29, after the Verifier had tagged claims 1-120. For every pillar resting on those claims, the grading is a reconstruction. The limit on the damage is the one the loop record uses. Each class was set from what the register's "If it is false" column and the binding chair's position say breaks, not from the tag. Nothing in the file was refuted when the classes were set, so no grading here was chosen to keep a refutation away from a fatal pillar. Only claims 121-123 were untagged when these classes were set. This file appended them (see the last section).

Rebuilt the same day, after the first refutation (turn 3). Later on 2026-09-29 the Verifier re-checked the payment claims against the cached July 2026 DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee schedule. claim 107verified moved to verified and claim 117refuted to refuted, and B7 It is a business. A stock-sized… derived blocking. The loop record answers that with IR-20 claim 117 came back refuted (absorb). This rebuild keeps against_pivot: P0 the original shape, because pivot: has not moved and there is no new shape to restate the bet for. No consequence class was changed. claim 117refuted stays under B7 It is a business. A stock-sized…, where the first statement put it before the tag arrived. Moving a refuted claim to a softer pillar after the answer came back is the move this file's graded: dates exist to expose. What changed is the text around it: the bet's payment sentence, B7 It is a business. A stock-sized…'s settled by:, the rental shape among the neighbours, and the notes below.

Register coverage made some rests on: lists wider than this file would have drawn them. The checker requires every one of the loop record's 63 live register rows to sit under some pillar. Each row is placed where its own "If it is false" column lands. Where that pulled in a verified claim the pillar would survive without, and so lifted a standing, the last section says so (B1 Worn in its own configuration, B3 Medicare pays for it, B7 It is a business. A stock-sized…, B8 Nothing stands between the device and a US…).

The bet

A neurologist or autonomic specialist has a patient with PD, MSA or pure autonomic failure who still gets dizzy or faint on standing, despite fluids, salt and stockings. Today that patient gets midodrine or droxidopa claim 11unconfirmed, through the pharmacy benefit, with a supine-hypertension liability. The bet is that the specialist will instead write, or add, a prescription for a powered abdominal binder. The patient wears it under clothing all day. It inflates to about 40 mmHg when a posture sensor says the patient is upright and vents when they sit or lie down, so the treatment never acts while the patient is recumbent. Medicare Part B (Medicare Part B) pays for it as durable medical equipment under the pneumatic-compressor code family (E0650 (a HCPCS code for durable medical equipment)-E0652) claim 10unconfirmed. That family is paid as a purchase. The July 2026 fee schedule puts E0650-E0652 in the inexpensive-or-routinely-purchased category, not capped rental, which refutes the chair's reading that Medicare rents it claim 117refuted. So the P0 the original shape premise of a patient-owned purchase stands at the level of the code family. What the device would actually bill under is still open claim 40unconfirmed, and that choice alone moves the one-time payment by a factor of about seven, from E0650 to E0652. The shape is deliberately not built on a coverage-at-authorization pathway. RAPID is a notice not in force claim 15verified, and TCET is paused claim 16verified. The mechanism has one published randomized precedent claim 5verified. That study activated the binder manually, just before a stand of ten minutes or less claim 73verified. The design's defining feature, posture-triggered all-day inflation, therefore has no clinical precedent of its own. The claim to efficacy, the claim to safety and the claim to payment are all currently the file's own design intent.

The shapes it is not. Each survives a different pillar failing:

• Patient- or caregiver-activated inflation with automatic venting on recumbency. Four chairs named it independently (loop record, round table), and trigger T2 would move the opportunity there. It survives B2 Posture triggering is the right defining…. It is also the only configuration with clinical precedent. It does not survive B1 Worn in its own configuration, B5 People with PD or B6 Neurologists and autonomic specialists will….
• **A haemodynamic claim ("attenuates the orthostatic fall in blood pressure") instead of symptom burden and standing time.** This is trigger T1, the shape Clinical and Regulatory both name if NCT03482297 is null. It survives part of B1 Worn in its own configuration. What it does to B6 Neurologists and autonomic specialists will… and B3 Medicare pays for it (who prescribes, and what a coverage policy reads) is not graded here.
• A capped-term rental with a supplier-carried controller fleet. This was trigger T3. The fee schedule has now answered the question T3 was waiting on, in the other direction claim 117refuted, so T3 cannot fire from the compressor family (IR-20 claim 117 came back refuted). It stays on this list for one reason. The trunk and chest appliances (E0656, E0657) are capped rental. If CMS ever coded this device's garment as a trunk appliance, a partly rental shape would come back through the coding question (claims 40 and 115), not through T3.
• A 510(k) follower under 21 CFR (Title 21 of the Code of Federal Regulations) 870.5800. This is trigger T4. It survives B4 The route to market is a Class II De Novo…'s no-predicate leg failing, and it gives up the first-to-De Novo position. Market Access warns that it pulls the device toward NCD 280.6 (a Medicare national coverage determination number).
• An MSA/PAF-only indication. This is Clinical's named pivot if the effect is absent in Parkinson disease claim 101unconfirmed. It survives that leg of B1 Worn in its own configuration and shrinks B7 It is a business. A stock-sized…'s volume.
• The claim-stripped garment (device_class row 3). It survives B1 Worn in its own configuration, B3 Medicare pays for it and B4 The route to market is a Class II De Novo… by giving up the therapeutic claim. The candidate file calls it "a floor, not a plan".

Pillars

Eight. Four are graded fatal: the device must reduce symptoms (B1 Worn in its own configuration), Medicare must pay for it (B3 Medicare pays for it), patients must wear it (B5 People with PD), and specialists must prescribe it (B6 Neurologists and autonomic specialists will…). The margin (B7 It is a business. A stock-sized…) is a fifth. The other three each have a named shape waiting behind them in the loop record's pivot triggers or in the device_class routes. That is what grading them reshaping means here.

• B1 Worn in its own configuration Worn in its own configuration, posture-triggered at about 40 mmHg rather than manually pre-inflated for a short stand, the device reduces orthostatic symptom burden against a sham in primary autonomic failure, by a margin a prescriber would act on, including in Parkinson disease — consequence: fatal — graded: 2026-09-29 — rests on: claim 5verified, claim 46unconfirmed, claim 98unconfirmed, claim 100unconfirmed, claim 101unconfirmed — settled by: REQ-0137 Has any result of NCT03482297, a search of the NCT03482297 investigators' publications, conference abstracts and the NIH RePORTER outputs of award 5R01HL144568 for the one double-blind sham-controlled result of this mechanism. A posted or published null fires trigger T1. The settling artifact after that is Clinical's pre-specified 12-week pivotal (claim 100unconfirmed) — cost: cheap — in plain words: Worn the way it is designed, inflating to about 40 mmHg when the wearer stands, the belt has to reduce dizziness and fainting more than a sham does, by a margin a doctor would act on, including in people with Parkinson disease. If it does not, there is no product.
• B2 Posture triggering is the right defining… Posture triggering is the right defining feature. It inflates soon enough after standing to help, and in PD, MSA and PAF patients, including those with camptocormia and dyskinesia, it never holds pressure on a recumbent wearer beyond a bound that is harmless in a population where 30-46% have supine hypertension. It vents under every single fault through a path that does not depend on firmware — consequence: reshaping — graded: 2026-09-29 — rests on: claim 31unconfirmed, claim 45unconfirmed, claim 48unconfirmed, claim 49unconfirmed, claim 108unconfirmed, claim 109unconfirmed, claim 110unconfirmed, claim 111unconfirmed, claim 113unconfirmed — settled by: two answers that decide trigger T2 before anything is built. REQ-0117 If supine exposure to 40 mmHg abdominal…, Clinical's answer on whether a 60-second supine exposure is harmless in this population, and REQ-0119 Literature pass, the published false-upright rates for single trunk-worn sensors split by camptocormia and dyskinesia. After those come Technology's video-referenced classifier study and fault-injection bench rig — cost: cheap — in plain words: Inflating on standing has to be the right idea: quick enough to help, and never squeezing a wearer who is lying down for longer than is safe, in patients who often already have high blood pressure when lying flat. If posture triggering cannot be made safe, the device becomes a manually operated belt.
• B3 Medicare pays for it Medicare pays for it, for most of the patients who get it. The device is Part B durable medical equipment, both as a reusable three-year controller and as an item that is medical, not useful absent illness, and meant for the home. It can be billed under a code. A DME MAC or national coverage policy reaches nOH, and no existing NCD captures it first. Most prescribed patients are Medicare beneficiaries, and Medicare Advantage follows the Part B outcome — consequence: fatal — graded: 2026-09-29 — rests on: claim 10unconfirmed, claim 32unconfirmed, claim 33unconfirmed, claim 40unconfirmed, claim 41unconfirmed, claim 44unconfirmed, claim 115unconfirmed, claim 116verified, claim 118unconfirmed, claim 119unconfirmed, claim 120verified, claim 121unconfirmed — settled by: three document reads. REQ-0125 Full-text retrieval of DME MAC LCD L33829… (the full text of LCD L33829 and its policy article), REQ-0147 What evidentiary standard does Medicare… (the written evidentiary standard a DME MAC LCD or an NCD applies), and a read of 42 CFR 414.202 and the Medicare Benefit Policy Manual's DME chapter against conditions (3)-(5) (claim 121unconfirmed). The CMS acts themselves are post-authorisation and human — cost: cheap — in plain words: Medicare has to pay for it as home medical equipment, under an existing billing code, with a coverage rule that reaches this condition, and most patients have to be on Medicare. If Medicare does not pay, there is no payer and no business.
• B4 The route to market is a Class II De Novo… The route to market is a Class II De Novo on clinical data of the NCT03482297 design, with the 870.5800 510(k) repositioning kept open. No cleared device already carries the indication, and no other sponsor gets there first — consequence: reshaping — graded: 2026-09-29 — rests on: claim 3unconfirmed, claim 34unconfirmed, claim 52verified, claim 55verified, claim 102unconfirmed, claim 103unconfirmed, claim 104verified, claim 105unconfirmed, claim 106unconfirmed — settled by: REQ-0135 Is there any FDA 510 (an indication-level search, and whether FOIA is the only route to the six pre-1996 anti-shock trouser IFUs), REQ-0136 Who else is developing a powered (the competitor sweep, starting from Isotech ISO-101), then the Pre-Submission question set drafted under REQ-0142 Draft the Pre-Submission and filed by a human — cost: project — in plain words: The route to market is a De Novo request on clinical data, with no cleared device already carrying this use and no competitor getting there first. If a competitor or a different route appears, the plan changes shape.
• B5 People with PD People with PD, MSA or PAF, with tremor, rigidity and impaired dexterity, will don, charge and operate a powered abdominal garment every day. They will tolerate sustained compression through every upright period, and feel enough relief in the first weeks to keep wearing it — consequence: fatal — graded: 2026-09-29 — rests on: claim 28unconfirmed, claim 38unconfirmed, claim 39unconfirmed, claim 99unconfirmed — settled by: Clinical's 4-week single-arm home-use feasibility study in at least 20 adults (claim 99unconfirmed), with the donning, early-benefit and tolerance endpoints REQ-0141 Can the home-use feasibility study in your… asks for. It needs a built device — cost: funded — in plain words: People with Parkinson disease and similar conditions, who shake, are stiff and struggle with their hands, have to put on, charge and run a powered belt every day, tolerate the squeeze whenever they are upright, and feel enough relief early on to keep wearing it. If they stop wearing it, there is no business.
• B6 Neurologists and autonomic specialists will… Neurologists and autonomic specialists will prescribe a DME device into an indication they manage with midodrine and droxidopa, and will carry the prescription and prior-authorisation paperwork. The reason they do is a difference those drugs' labels actually leave open: no treatment effect while supine — consequence: fatal — graded: 2026-09-29 — rests on: claim 11unconfirmed, claim 29unconfirmed, claim 30unconfirmed — settled by: the prescriber instrument REQ-0140 Specify the primary research that would… asks Commercial to specify, fielded as structured calls to 15-20 movement-disorder neurologists and autonomic specialists, plus REQ-0138 What do the current FDA labels for… (the midodrine and droxidopa label text, with set IDs) — cost: cheap — in plain words: Neurologists and autonomic specialists have to prescribe a piece of equipment for a condition they currently treat with two drugs, and handle the paperwork, because the belt does something those drugs cannot: it does not raise blood pressure when the patient lies down. If they will not prescribe it, there is no business.
• B7 It is a business. A stock-sized… It is a business. A stock-sized controller-plus-garment system, built from dual-source parts through a standard test campaign, costs less per patient than Medicare pays for it, at the allowable and in the cadence Medicare actually pays, including the garments that wear out. That holds at a volume the prescribable population supports and through a supplier channel that will carry it. The margin pays back the fixed programme — consequence: fatal — graded: 2026-09-29 — rests on: claim 22verified, claim 23unconfirmed, claim 24unconfirmed, claim 36unconfirmed, claim 37unconfirmed, claim 50unconfirmed, claim 92unconfirmed, claim 93unconfirmed, claim 94unconfirmed, claim 95unconfirmed, claim 96unconfirmed, claim 97unconfirmed, claim 107verified, claim 112unconfirmed, claim 114unconfirmed, claim 117refuted, claim 122unconfirmed, claim 123unconfirmed — settled by: first REQ-0125 Full-text retrieval of DME MAC LCD L33829…, the full text of LCD L33829 and its policy article, which says whether replacement garments are paid separately (claim 122unconfirmed). With the compressor family now a one-time purchase (IR-20 claim 117 came back refuted absorbed the refutation of claim 117refuted), that is the only recurring line left. Then Operations' cost build-up (REQ-0123 What is the expected unit cost of goods, REQ-0114 What unit does the idea-019 money model…) against the published purchase allowables. The fetch REQ-0139 Find the CMS DMEPOS fee schedule file in… asked for has already been made (claims 107 and 117) — cost: cheap — in plain words: A standard-sized controller plus garment, built from parts with two suppliers each, has to cost less per patient than Medicare pays, including replacement garments, at a volume the patient population supports, through suppliers willing to stock it. If the margin is not there, there is no business.
• B8 Nothing stands between the device and a US… Nothing stands between the device and a US sale, and there is something to own. No granted, in-force claim of the Vanderbilt family, and no other live art, reads on posture-triggered or servo-controlled abdominal compression for OH without a licence that is actually available — consequence: reshaping — graded: 2026-09-29 — rests on: claim 26verified, claim 43unconfirmed, claim 88unconfirmed, claim 89unconfirmed, claim 90unconfirmed, claim 91unconfirmed — settled by: REQ-0110 Legal status and family of US2015313608, the legal status, family, granted claims and assignee of US2015313608 from the patent office record, then the CPC and assignee landscape in REQ-0111 A US patent landscape over…. An enquiry to the rights holder is a human act and a Tier 3 disclosure — cost: cheap — in plain words: No patent still in force, including a known university family, covers posture-triggered abdominal compression for this condition without a licence that can actually be had. If one does, the product needs a licence or a redesign.

Standing

Rendered, never written: python3 engine/scripts/check_assessment.py --candidate idea-019 --render

Decision queue

Same render. Worst exposure first; inside a band, cheapest first.

Regrades

None. The first statement set every class on 2026-09-29. The turn-3 rebuild the same day changed no class. B7 It is a business. A stock-sized… stays fatal with claim 117refuted under it (see the note at the top), and B7 It is a business. A stock-sized…'s cost: stays cheap because its first move is now REQ-0125 Full-text retrieval of DME MAC LCD L33829… instead of the fetch that has already been made.

What this does not say

• B7 It is a business. A stock-sized… reads blocking, but nothing refuted a premise of the business. The misreading this rebuild invites most is to see the top of the queue as the fatal pillar being knocked out. It was not. claim 117refuted was Market Access's counter-reading of P0 the original shape's cadence: it said Medicare rents the compressor family. P0 the original shape was built on the opposite, a purchase (claims 23 and 96, and the design note). The fee schedule came back on P0 the original shape's side. B7 It is a business. A stock-sized… cites claim 117refuted only because register row A60 In the CMS DMEPOS fee schedule is live and every live row needs a pillar. The instrument counts a refutation as a hole whichever direction it points, and has no column for direction. That is the same limit noted for claim 26verified under B8 Nothing stands between the device and a US… below.
  • What answers it: IR-20 claim 117 came back refuted in the loop record, outcome absorb, which names each dependant and why it survives.
  • What the posture means here: repair-pending is derived from blocking and cannot tell an absorbed hole from an unanswered one. Here the review has been run. What is still pending is the Market Access re-statement of C3, not a repair to the business.
  • What B7 It is a business. A stock-sized… would really die on: Read B7 It is a business. A stock-sized… as critical. It turns on the claims B7 It is a business. A stock-sized… would die without, and none of them has an answer: claim 96unconfirmed, COGS (cost of goods sold) under a one-time purchase allowable; claim 122unconfirmed, whether replacement garments are paid separately, now the only recurring line; and claim 123unconfirmed, whether the margin repays the programme. Which allowable applies is B3 Medicare pays for it's claim 40unconfirmed, and it swings the denominator about seven-fold.
  • What this rebuild did not do: It did not move claim 117refuted to a softer pillar to make the word go away (see the note at the top).
• Only two pillars show critical, and five are fatal in effect. B1 Worn in its own configuration and B3 Medicare pays for it are graded fatal but read high, because each rests on at least one verified claim and the matrix turns fatal-plus-partial into high. B7 It is a business. A stock-sized… is covered by the note above. In neither of the two does the verified claim settle the part of the proposition that could end the business:
  • B1 Worn in its own configuration is partial because of claim 5verified. That is a 19-patient single-blind crossover in which the binder was inflated by hand, less than two minutes before a stand of ten minutes or less claim 73verified. It is the precedent for the mechanism, not for this device, and the one double-blind trial of the mechanism has posted no result claim 98unconfirmed. Read B1 Worn in its own configuration as critical.
  • B3 Medicare pays for it is partial because of claim 116verified and claim 120verified. claim 116verified says NCD 280.6 describes an intermittently inflated limb garment. That is Market Access's argument that the NCD does not capture this device. It is not evidence that any policy covers it. claim 120verified says Medicare Advantage follows the Part B outcome, whichever way the outcome goes. It sits here because register row A63 42 CFR 422.101 cites it, and B3 Medicare pays for it would survive without it. Every claim about whether this device is DME, gets a code, or gets coverage is unconfirmed. Read B3 Medicare pays for it as critical. B7 It is a business. A stock-sized…'s two verified claims do not lift it either. claim 22verified is a pooled prevalence of orthostatic hypotension in Parkinson disease: a population, with no price, share or cost. claim 107verified says the allowables are published. It does not say that any of them pays for this device. The table is left as rendered. Patching a rendering would turn it into a memory.
• The queue puts a funded study third, and that is not an instruction to fund it next. B5 People with PD is #3 because it is critical, and inside a band the queue sorts only by cost. Across the five fatal pillars, four have a cheap first move: prescriber calls (B6 Neurologists and autonomic specialists will…), a literature and NIH RePORTER search (B1 Worn in its own configuration), three CMS document reads (B3 Medicare pays for it), and one LCD-and-article read (B7 It is a business. A stock-sized…, REQ-0125 Full-text retrieval of DME MAC LCD L33829…, which B3 Medicare pays for it also names). B5 People with PD is the only one that needs a built device. The fee-schedule fetch that was B7 It is a business. A stock-sized…'s first move is done. The loop record already calls B1 Worn in its own configuration's first move, REQ-0137 Has any result of NCT03482297, "the cheapest decisive item on the file". It sits at #4 only because claim 5verified lifted B1 Worn in its own configuration out of critical. It was stated in advance that a posted or published null result is a finding about the world and routes to trigger T1, not to another commission.
• The grading most open to argument is B4 The route to market is a Class II De Novo… at reshaping. B4 The route to market is a Class II De Novo… fails in three ways: a predicate exists, a competitor reaches De Novo first, or FDA (US Food and Drug Administration) says Class III (FDA device class III) claim 102unconfirmed. The first two leave a 510(k)-follower business, which is reshaping, or arguably only costly. The third means a PMA (premarket approval)-scale programme for a device whose market has no price yet (B7 It is a business. A stock-sized…). A reader could fairly say that for a standalone developer this ends the business, and grade B4 The route to market is a Class II De Novo… fatal. It is graded reshaping because a Class III finding changes who can carry the programme, for example a licence to an incumbent, not whether a device can reach patients. That reading assumes such a sponsor exists, which no claim states. If B4 The route to market is a Class II De Novo… is argued up, it goes in ## Regrades, not into a quiet edit.
• B2 Posture triggering is the right defining… at reshaping should be argued with too, from the other direction. If posture triggering cannot carry a safety case, the fallback that four chairs name is patient-activated inflation with automatic venting. It is the only configuration with clinical precedent, so failing B2 Posture triggering is the right defining… may leave a better-evidenced product, not a worse one. What B2 Posture triggering is the right defining…'s failure costs the business is the named differentiation: "no pressure while supine" becomes "vents on recumbency". That is B6 Neurologists and autonomic specialists will…'s reason to prescribe. This file does not grade how the pillars interact. The standing arithmetic has no column for B2 Posture triggering is the right defining… failing and B6 Neurologists and autonomic specialists will… thereby weakening.
• B3 Medicare pays for it and B7 It is a business. A stock-sized… at fatal, not reshaping, is a choice. Cash pay claim 36unconfirmed and commercial payers (REQ-0146 Retrieve the current medical/coverage…) are the neighbouring shapes if Medicare does not pay or pays too little. They are graded as no business, not a different one. The indicated population is predominantly older (claims 58, 59, 83 give ages from registry and claims records), and no claim gives cash-pay or commercial volume a size. A reader who thinks a cash-pay premium device is a real business for this population should grade B3 Medicare pays for it down.
• B7 It is a business. A stock-sized… is wide, and most of its claims are costly-grade. Claims 93, 94, 95, 97 and 114 (biocompatibility category, test standards, the JOW recall census, dual sourcing and battery life) each change schedule or cost, not shape. They sit under a fatal pillar because their register rows land on the cost of goods, and because B7 It is a business. A stock-sized… is where cost lives. None is verified, so none moves the standing. The claims B7 It is a business. A stock-sized… would die without are 96, 122 and
  1. claim 107verified is an input to them, and claim 117refuted is the refuted counter-reading covered in the first note. claim 124unconfirmed (the business case's supplier-inventory revenue model) is not cited at all. It is not in the register, and its capped-rental premise is the one the fee schedule contradicts. The same applies to the four claims IR-17 claims 91 and 95 came back exact and are…, IR-18 claim 90 came back unconfirmed and IR-19 claim 105 came back unconfirmed absorbed: claim 95unconfirmed (B7 It is a business. A stock-sized…), claims 90 and 91 (B8 Nothing stands between the device and a US…) and claim 105unconfirmed (B4 The route to market is a Class II De Novo…). They are cited for register coverage only. Their presence does not mean they bear weight, and the loop record says why each does not.
• B8 Nothing stands between the device and a US… at moderate is lifted by claim 26verified. That claim verifies that an on-mechanism family exists and is live on a naive term to 2033. It is adverse to B8 Nothing stands between the device and a US…, not support for it. The instrument cannot read direction. Grant status, claim scope and licence availability are all unread (claims 43, 88, 89), and Legal abstains until REQ-0110 Legal status and family of US2015313608 returns.
• No pillar came out unexamined, and that does not mean nothing was missing. The loop record had already turned its three unstated propositions into claims 89, 96, 102 and 106. This file found three more legs that no claim stated, and appended them as unverified:
  • claim 121unconfirmed: DME conditions (3)-(5). claim 119unconfirmed reaches only (1)-(2), and an abdominal garment could fail "not useful absent illness" on its own.
  • claim 122unconfirmed: separate payment for replacement garments. The controller-plus-garment architecture in claim 92unconfirmed assumes it, and no one had written it down.
  • claim 123unconfirmed: whether the margin repays the fixed programme. claim 96unconfirmed is a per-unit test. It says nothing about paying for a prototype, two studies, a De Novo, a coding application and a coverage request. None of the three is a finding. No connector reads claim 123unconfirmed. A business case is the artifact that could bear on it, and it would read as a model, not a source. Claims 124-135 are not cited by any pillar, and that is not an oversight. The business case and the three decks appended them after this file was first stated. None is in the register, and none was bound by a chair. Three of them bear on pillars and would be the first candidates if the register grows:
  • claim 129unconfirmed, garment life under twelve months (B7 It is a business. A stock-sized…'s recurring line);
  • claim 127unconfirmed, the claim-stripped floor under 21 CFR 801.4 (the row-3 shape);
  • claim 135unconfirmed, efficacy below 40 mmHg (B1 Worn in its own configuration and B5 People with PD). Registering them is a front-end register decision, not an assessment one. Citing them here without that decision would pad pillars with claims the front end has not called load-bearing.
• **Exposure is not truth, resolved is not a pass, and nothing here ranks idea-019 against another opportunity.** No pillar is resolved. repair-pending is a state. It is derived from B7 It is a business. A stock-sized…'s blocking, and the first note says what that does and does not mean here. It does not say the opportunity is worth money, and it does not say it is broken. The verified composite (25/100) and the cleared gate are a different axis. Neither moves anything here, and nothing here moves them. Whether any of the funded or human acts named above (the feasibility study, the Pre-Sub, the rights-holder enquiry, the fieldwork) should happen is Tier 3.

Every claim in the candidate file, with the pillars that rest on it and the materiality it inherits from them. 66 of 142 are read by a pillar; the rest are context — true, possibly checked, and carrying nothing. That is not an insult and it is not an error: it is the only view in this repo that can tell you where the verification effort went.